Latest Breaking News On - Ophthalmology innovation summit - Page 4 : comparemela.com

Hovione completes its Phase 2 clinical trial of the first minocycline ophthalmic showing promise in Dry Eye Disease associated with Inflamed Meibomian Gland Dysfunction News provided by Share this article Share this article CORK, Ireland, March 17, 2021 /PRNewswire/  Hovione announced at the Ophthalmology Innovation Summit (OIS) Dry Eye Showcase the successful completion of its Phase 2 clinical trial in 270 patients with Dry Eye caused by Meibomian Gland Dysfunction (MGD). The well controlled and representative study was conducted across 26 clinical sites in the United States and tested 2 different strengths of minocycline against vehicle in a 1:1:1 randomization. This is the first dry eye therapy targeting MGD patients with ocular inflammation demonstrated by an MMP-9 based diagnostic and the first and only ophthalmic formulation of minocycline in clinical development, contingently named Meizuvo®.

United statesNew jerseyIsabel pinaGeorge magrathCarla vozoneCourtney smithContract developmentBusiness development licensingLexitas pharma servicesManufacturing organizationOphthalmology innovation summitDry eye showcaseDry eyeMeibomian gland dysfunctionVisual analogue scaleCornea fluorescein staining